Back to today’s briefing

Story perspectives

Ohio Clinics Face Scrutiny Over Unapproved Weight-Loss Drugs

1/28/2025

45 8

Summary

Story summary

Ohio clinics have faced license revocations for distributing unapproved weight-loss drugs marked “For Research Use Only.” The soaring demand for GLP-1 medications, such as Ozempic and Wegovy, has sparked safety concerns. Meanwhile, in the Netherlands, a surge in private prescriptions has ignited discussions about the broader societal implications and health risks associated with these treatments.

1 of 1

Story summary

Ohio clinics have faced license revocations for distributing unapproved weight-loss drugs marked “For Research Use Only.” The soaring demand for GLP-1 medications, such as Ozempic and Wegovy, has sparked safety concerns. Meanwhile, in the Netherlands, a surge in private prescriptions has ignited discussions about the broader societal implications and health risks associated with these treatments.